Presentación de PowerPoint
A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery | Scientific Reports
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Pa
How Good Are Controlled Attenuation Parameter Scores from Fibroscan to Assess Steatosis, NASH, and Fibrosis? | SpringerLink
Transient elastography versus liver biopsy: discordance in evaluations for fibrosis and steatosis from a pathology standpoint | Modern Pathology
Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery | Scientific Reports
Individual patient data meta-analysis of controlled attenuation parameter ( CAP) technology for assessing steatosis - ScienceDirect
Diagnostics | Free Full-Text | Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan
Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis - eClinicalMedicine
Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis - eClinicalMedicine
PDF) Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease
How Good Are Controlled Attenuation Parameter Scores from Fibroscan to Assess Steatosis, NASH, and Fibrosis? | SpringerLink
FibroScan - Because liver health matters
Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease
Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery | Scientific Reports
Non-invasive tests of non-alcoholic fatty liver disease | Chinese Medical Journal
Frontiers | Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment
Diagnostics | Free Full-Text | Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan
CAP cutoff values for the diagnosis of steatosis grades ≥S1, ≥S2, and ≥S3 | Download Table
Clinical and Molecular Hepatology
Frontiers | Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement
FibroScan - Because liver health matters
